Predictors of premature termination and completion of randomized controlled trials

Giovanni J Soletti; Katia Audisio; Gianmarco Cancelli; Mohamed Rahouma; Arnaldo Dimagli; Lamia Harik; Roberto Perezgrovas Olaria; Talal Alzghari; Kevin R An; Hillary Polk; Hillary Lia; Derrick Y Tam; Stephen E Fremes; Mario Gaudino

doi:10.1016/j.cct.2023.107219

Predictors of premature termination and completion of randomized controlled trials

Contemp Clin Trials. 2023 Jul:130:107219. doi: 10.1016/j.cct.2023.107219. Epub 2023 May 6.

Affiliations

¹ Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
² Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
³ Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA. Electronic address: [email protected].

PMID: 37156372
DOI: 10.1016/j.cct.2023.107219

Abstract

Randomized clinical trials (RCTs) have a key role in progressing biomedical research and guiding clinical decision making, but premature termination remains high (up to 30%), raising concerns regarding funding expenditure and resource allocation. This brief report sought to identify variables associated with RCTs' premature termination and completion.

Keywords: ClinicalTrials.gov; Completion; Industry; Predictors; Randomized clinical trials; Sponsor; Termination.

MeSH terms

Biomedical Research*
Humans
Randomized Controlled Trials as Topic